employees.

- Special Situations: There is a rising concern with the use of immunotherapy (or agents that might impact the immune system) and the potential for it to exacerbate or negatively impact the immune response in patients who contract COVID-19. Currently, no agency has restricted the use of these agents, but we believe issues should at least be discussed with enrolled patients regarding continued use of immunotherapy. If alternative and equally effective treatments are available, we recommend choosing the alternative treatment at this time. The USA Health Clinical Trials Office will continue to monitor these situations and plan on notifying any changes in recommendations as soon as possible.
- <u>Future:</u> The USA Health Clinical Trials Office will continuously monitor this situation, with attention to recommendations from Food and Drug Administration and/or other national organizations, in order to provide additional guidance for patients enrolled on USA Health Clinical Trial protocols.

•